Mainz, Germany, October 27, 2021 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=-N4HWcBprBQdgJyKg_3U4H_SJpqHdmyAjIVxwZeOCOuH4jSGrb01Oy0gr5ToZITycKsnrqFDz3PMv9YU_Q4HEA== BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the third quarter on Tuesday, November 9(th) , 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. ET (2.00 p.m. CET) to report its financial results and provide a corporate update for the third quarter 2021.
The slide presentation and audio of the webcast will be available via this https://www.globenewswire.com/Tracker?data=NilPeSSMQGp2rxYRZ4U5VY1Fz89dCAmKokmhaeh7eBgpXyx8haofV92DxdRMvLQxtyL0U4u4M6nG7LcAGHqW9Q4pu1yyxZAnghVV3QB8gBw= link.
To participate in the conference call, please dial the following numbers ten minutes prior to the start and provide the Conference ID:
United States international: +1 646 741 3167
United States domestic (toll-free): +1 877 870 9135
Germany: +49 (0) 692 2222 625
Conference ID: 6835174
Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor Relations section of the Company's website at https://www.globenewswire.com/Tracker?data=LtKFmpO2Zm1xwLQ480qJCkMDXHcQzgHDDtSGRPU3pRklQ6xZYBk25zedathRIDB_MiuLVg7-Vt1GLhDPu724DQ== https://biontech.de/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
For more information, please visit https://www.globenewswire.com/Tracker?data=sR5QO5f3CubmBVlM5yaVgyFp53yDMUeuTNpfGLc9YMRuzvpv9lm46NCAkI01Ayeh7mUywQ2aHgdHMA79pyBccw== www.BioNTech.de.
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
+49 (0)6131 9084 1513
(END) Dow Jones Newswires
October 27, 2021 07:00 ET (11:00 GMT)